Patients Begin Enrolling in Studies to Determine if Women With BRCA 1 & 2 Positive Cancer may Receive Greater Benefit From New Treatment


    - AstraZeneca Collaborates With Myriad Genetics on Phase 2 Trials

    ALDERLEY PARK, England, June 19 /CNW/ - AstraZeneca (NYSE:   AZN) today
announced the start of two Phase II trials for a new compound being tested to
treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad
Genetics, Inc. (Nasdaq:   MYGN,, is providing the molecular
diagnostic testing (BRACAnalysis(TM)) for these trials.
    The ICEBERG (International Collaborative Expertise for BRCA Education and
Research through Genetics) studies are intended to evaluate the ability of
AZD2281 (KU-0059436), a PARP (poly-ADP-ribose polymerase) inhibitor, to treat
patients with breast cancer or ovarian cancer associated with an inherited
mutation in one of the cancer genes, BRCA1 or BRCA2.
    The BRCA1 and BRCA2 genes are involved in DNA repair and when this
function is lost due to a mutation, cells are unable to repair breaks in DNA.
Research has shown that women who inherit faults in either the BRCA1 or BRCA2
genes are predisposed to a higher incidence of breast and ovarian cancer. It
is hypothesised that PARP inhibitors work by inhibiting DNA repair in the BRCA
deficient tumour cells, thereby overloading these cells with DNA damage and
selectively killing these cells. The trials will evaluate the extent of
patient response to the treatment and time to disease progression amongst
other indicators of clinical benefit.
    Lead Investigator for the trials, Dr Andrew Tutt, clinician scientist at
the Breakthrough Breast Cancer Research Centre and breast oncologist at Guy's
Hospital, London, said: "Having demonstrated the potential of PARP inhibitors
through lab work carried out at the Breakthrough Research Centre, we hope
these trials will help us confirm the results in the clinic, leading to the
development of a targeted treatment for this type of cancer."
    Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc.
added "There is enormous potential for patient benefit from the synergy
between the molecular diagnosis of breast or ovarian cancer and a specific,
targeted therapeutic. Myriad's BRACAnalysis(TM) test is a highly sensitive
proven method for finding mutations in BRCA1 and BRCA2. The individuals with
breast or ovarian cancer who carry these mutations are candidates for the PARP
inhibitor therapy approach. It may become more important than ever to know
whether a patient with breast or ovarian cancer is BRCA1 or BRCA2 mutation

    Study Details

    The two studies will enrol up to 40 patients each:

    -  Breast study: phase II, open-label, non-comparative, international,
       multicentre study to assess the efficacy and safety of AZD2281 given
       orally in patients with advanced BRCA1- or BRCA2-associated breast

    -  Entry criteria - measurable advanced breast cancer (stage
       IIIB/IIIC/IV) and confirmed BRCA+ status.

    -  Ovarian study: phase II, open-label, non-comparative, international,
       multicentre study to assess the efficacy and safety of AZD2281 given
       orally in patients with advanced BRCA1- or BRCA2-associated ovarian

    -  Entry criteria - measurable advanced ovarian cancer (stage
       IIIB/IIIC/IV) and confirmed BRCA+ status.

    Notes to Editors:

    - AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of
US$26.47 billion and leading positions in sales of gastrointestinal,
cardiovascular, neuroscience, respiratory, oncology and infection products.
AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well
as the FTSE4 Good Index. For more information about AstraZeneca, please visit:

    - Breakthrough Breast Cancer is the UK's leading charity committed to
fighting breast cancer through research, campaigning and education. Our vision
is a future free from the fear of breast cancer. More information can be found
at: or through the Breakthrough Information Line

    - Breakthrough Breast Cancer has established the UK's first dedicated
breast cancer research centre, in partnership with The Institute of Cancer
Research, - The Breakthrough Toby Robins Breast Cancer Research Centre
situated in the Mary-Jean Mitchell Green Building, Chester Beatty
Laboratories, The Institute of Cancer Research. Under the directorship of
Professor Alan Ashworth, its 100 scientists and clinicians are working on a
programme of cutting edge biological research that ultimately aims to
eradicate breast cancer, by discovering the causes of the disease, finding
methods of prevention and developing new treatments and more effective

    - BRACAnalysis(TM) is a trademark of Myriad Genetics, Inc. in the United
    States and other countries.

    - Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of novel healthcare products. The Company develops and markets
predictive medicine products, and is developing and intends to market
therapeutic products. Myriad's news and other information are available on the
Company's Web site at

    - KuDOS Pharmaceuticals Ltd is a wholly-owned subsidiary of AstraZeneca.
AZ acquired KuDOS Pharmaceuticals in Feb 2006. KuDOS research is focused on
the discovery of molecules to treat cancer in the area of DNA repair

    - KuDOS Pharmaceuticals will run the international, multi-center clinical
trial and reimburse Myriad for provision of the molecular diagnostic testing
for the trial. Myriad will have exclusive worldwide rights to diagnostic
applications of the findings from the study and KuDOS, all rights to its
therapeutic and its applications.

For further information:

For further information: Carrie Deverell, Global Public Relations
Manager, AstraZeneca, Mobile: +44-(0)7920845108,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890